NCT02920359已完成1 期
Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control
Parc de Salut Mar0 个研究点目标入组 5 人开始时间: 2016年11月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5
- 主要终点
- Urine concentrations of leuprorelin acetate
研究概览
简要总结
The study consists of the generation of biological samples (in urine) positive to leuprorelin acetate for doping control by new developed methods, and establish the analytical parameters that reveal the administration of Leuprorelin acetate in healthy volunteers with these methods.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male volunteers aged from 18 to 45 years.
- •Understanding and accepting the study procedures and signing the informed consent form.
- •A health profile devoid of organic or physiological disorders.
- •The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.
- •Body mass index (BMI=weigh/height2) will range between 19 and 25 Kg/m2 and weight between 50 and 100 kg. BMI between 25 and 27 kg/m2 can be included by principal investigator criteria.
排除标准
- •Non compliance of the inclusion criteria.
- •History of allergy, idiosyncrasy, hypersensitivity or adverse reactions to the active substance, similar nonapeptides or any excipients.
- •History of allergy or adverse reactions to any medication.
- •Subjects for which the drug involved in the study is counter indicated.
- •History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs.
- •History or clinical evidence of alcoholism, drug abuse, or regular use of psychoactive drugs.
- •Have been volunteer in another study with drugs in the last 3 months prior to start this study.
- •Have taken part in studies with blood donation in the last 2 months prior to start this study.
- •Having suffered any organic disease or major surgery in the six months prior to start this study.
- •A prior history of or presence of significant cardiovascular, neurological, haematological, psychiatric, hepatic, gastrointestinal, pulmonary, endocrine, immunologic or renal disease that, in the investigator's opinion, considering the current state of the art, they are clinically significant, are life-threatening for the subjects and could interfere with the product assessment. Especially seizures or a history of epilepsy.
- •Regular use of any drug in the month prior to the study sessions, except for vitamins, herbal remedies or dietary supplements if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. The treatment with single or limited doses of symptomatic medicinal products in the week prior to the study sessions will not be a reason for exclusion if it is calculated that it has been cleared completely the day of the experimental session.
- •Smokers of more than 20 cigarettes per day in the last 3 months prior to start this study.
- •Taking more than 40 g of alcohol per day.
- •Drinking more than 5 cups per day of coffee, tea, coke, stimulants or equivalent, or drinks containing xanthines, in the 3 months prior to start this study.
- •Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
- •Subjects with positive serology for hepatitis B, C or HIV.
- •Subjects with anormal values of testosterone or prostate-specific antigen according to age normal values.
研究组 & 干预措施
LEUPRORELIN ACETATE
Experimental
干预措施: LEUPRORELIN ACETATE (Drug)
结局指标
主要结局
Urine concentrations of leuprorelin acetate
时间窗: From the administration to 6 hours post-administration
Urine samples will be collected in two intervals after the administration of leuprorelin acetate (0-3h; 3-6h) in all experimental study sessions (3 consecutive days).
次要结局
未报告次要终点
研究者
Rafael de la Torre
PhD
Parc de Salut Mar
相似试验
已完成
1 期
Generation of Positive Biological Samples to Epoetin for Doping Control.There Are no Conditions Under Study. Healthy VolunteersNCT02920372Parc de Salut Mar2
招募中
不适用
Assess Urine Biomarkers to Predict Nephropathy in Fabry DiseaseFabry DiseaseNCT06065605Lysosomal and Rare Disorders Research and Treatment Center, Inc.40
尚未招募
不适用
Detection of Lipoarabinomannan in Urine Evaluation of the STANDARDTMF TBLAMFIA and Its Impact on the Initial TB DiagnosisDiagnoses DiseaseTuberculosisNCT06306430Ospedale San Raffaele550
终止
不适用
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate CancerProstate CancerNCT03256630Genomic Health®, Inc.128
已完成
不适用
Urine Albendazole Levels for Coverage AssessmentHelminthiasisNCT04041427Universidad Nacional de Salta12